Outcome and risk prediction of early progression in patients with extranodal natural killer/T cell lymphoma from the CLCG study

Recently, progression-free survival at 24 months (PFS24) was defined as clinically relevant for patients with extranodal NK/T cell lymphoma. Herein, the clinical data from two independent random cohorts (696 patients each in the primary and validation datasets) were used to develop and validate a ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jia-Ying, Hou, Xiao-Rong, Chen, Si-Ye, Liu, Xin, Zhong, Qiu-Zi, Qian, Li-Ting, Qiao, Xue-Ying, Wang, Hua, Zhu, Yuan, Cao, Jian-Zhong, Wu, Jun-Xin, Wu, Tao, Zhu, Su-Yu, Shi, Mei, Zhang, Hui-Lai, Zhang, Xi-Mei, Su, Hang, Song, Yu-Qin, Zhu, Jun, Zhang, Yu-Jing, Huang, Hui-Qiang, Wang, Ying, He, Xia, Zhang, Li-Ling, Qu, Bao-Lin, Yang, Yong, Hu, Chen, Deng, Min, Wang, Shu-Lian, Qi, Shu-Nan, Li, Ye-Xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444649/
https://www.ncbi.nlm.nih.gov/pubmed/37306711
http://dx.doi.org/10.1007/s00277-023-05311-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444649/
https://www.ncbi.nlm.nih.gov/pubmed/37306711
http://dx.doi.org/10.1007/s00277-023-05311-5

Ejemplares similares